Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.
CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback